Comparative Pharmacology
Head-to-head clinical analysis: PENBRITIN S versus V CILLIN K.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENBRITIN S versus V CILLIN K.
PENBRITIN-S vs V-CILLIN K
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillinase-sensitive penicillin; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Penicillin V exerts bactericidal activity by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
250-500 mg orally every 6 hours or 500 mg-1 g intramuscularly/intravenously every 4-6 hours for moderate to severe infections.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections.
None Documented
None Documented
0.5-1 hour; prolonged in renal impairment (up to 7-10 hours in anuria).
0.5–1 hour (normal renal function); prolonged to 2–6 hours in renal impairment.
Renal: 75-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: ~10%.
Renal: 60-90% unchanged via tubular secretion and glomerular filtration; minor biliary/fecal: <10%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic